ShapeTX has expanded its collaboration with Roche by introducing a new target to their ongoing partnership. This development marks the commencement of a unique program where ShapeTX will utilize its exclusive AI-powered RNA editing platform to create a potential one-time therapy for an undisclosed disease affecting a substantial global population. 

Throughout the collaboration, ShapeTX will conduct preclinical research to pinpoint and present development candidates identified through its AI-powered RNAfix™ platform. Roche will take charge of the final preclinical and clinical development, as well as the global commercialization of any potential products resulting from this cooperative effort.

As per the agreement's terms, ShapeTX will receive a milestone payment and is eligible for development, regulatory, and sales milestone payments. Additionally, ShapeTX is entitled to receive tiered royalties based on the future sales of products emerging from this collaborative venture. The partnership is recognized for its outstanding nature, driven by a shared commitment to advancing new frontiers in genomic medicine.

Source: globenewswire.com